Level 1 — Absolute Beginner
Some older people get a sickness called Alzheimer's. It makes them forget things, even names of people they love. It is very sad for families.
There is a medicine that can help in the early days of the sickness. The name of the medicine is lecanemab. The medicine has a brand name too. It is called Leqembi.
Right now, people get the medicine in a hospital. A nurse puts it into the arm with a thin tube. This takes a long time and people must travel.
Soon, the medicine could come in a small pen. People can use the pen at home, one time each week. The U.S. health office is checking now if this is safe.
- sick
- Not well; having a problem with health.
- medicine
- Something we take to feel better when we are sick.
- forget
- To not remember something.
- old
- Having lived for many years.
- hospital
- A place where doctors help sick people.
- nurse
- A person who helps doctors and takes care of sick people.
- home
- The place where you live.
- week
- A period of seven days.
Level 2 — Elementary
Alzheimer's disease is a brain illness that mostly affects older people. It slowly damages the brain and makes it hard to remember things, follow conversations, or do everyday tasks. There is no full cure yet.
A medicine called lecanemab, sold as Leqembi, can slow down the disease in its early stages. It works by clearing a sticky protein called amyloid out of the brain.
Until now, patients had to go to a clinic every two weeks to receive the medicine through a vein. The visit lasts about an hour, and many patients find it tiring or hard to arrange.
Now the U.S. Food and Drug Administration, called the FDA, is reviewing a new form of the drug. It is a once-a-week auto-injector pen, called Leqembi Iqlik, that patients or caregivers can use at home. A decision is expected in May 2026, and many doctors hope it will make treatment much easier.
- disease
- An illness that makes the body or mind not work properly.
- brain
- The part of the body inside the head that controls thoughts and movements.
- cure
- Something that makes a sick person fully better.
- protein
- A small building block in the body, useful or harmful in different forms.
- vein
- A tube in the body that carries blood back to the heart.
- auto-injector
- A pen-like tool that gives a dose of medicine with one push.
- caregiver
- A person who looks after someone who is sick or old.
- treatment
- The medical care given to fight a disease.
Level 3 — Intermediate
The U.S. Food and Drug Administration is expected to decide in May 2026 whether to approve a subcutaneous formulation of lecanemab, marketed by Eisai and Biogen as Leqembi Iqlik, for patients with mild cognitive impairment or mild Alzheimer's dementia. If cleared, it would be the first amyloid-targeting Alzheimer's drug delivered as an at-home weekly injection rather than a hospital infusion.
Lecanemab is a monoclonal antibody designed to bind to and remove amyloid-beta plaques, the sticky protein clumps long associated with the progression of Alzheimer's disease. Clinical trials have shown a modest but statistically significant slowing of cognitive decline when the drug is started early in the disease course.
Today, lecanemab is administered as an intravenous infusion every two weeks at an outpatient clinic, an hour-long appointment that places real burdens on patients, caregivers, and rural families who must drive long distances. The new auto-injector pen is designed to be used by patients themselves or by caregivers in their own kitchens or living rooms once a week.
Approval would still come with caveats. Lecanemab carries a black-box warning for amyloid-related imaging abnormalities, which can include brain swelling and small bleeds, and patients still require periodic MRI monitoring. Even so, neurologists say a home option could meaningfully expand access to early-stage Alzheimer's treatment in the United States.
- subcutaneous
- Given by injection just below the skin.
- formulation
- The specific form a drug takes, such as pill, IV, or injection.
- monoclonal antibody
- A lab-made protein that binds to a specific target in the body.
- amyloid-beta
- A protein fragment that can clump in the brain and is linked to Alzheimer's.
- plaque
- A sticky deposit that builds up in tissue or vessels.
- intravenous
- Delivered into a vein.
- outpatient
- Care given without an overnight hospital stay.
- MRI
- A medical scan that uses magnets and radio waves to make pictures of the body.
Level 4 — Advanced
The U.S. Food and Drug Administration is expected this month to issue a decision on a subcutaneous formulation of lecanemab-irmb, branded Leqembi Iqlik by Eisai and Biogen, for adults with mild cognitive impairment or mild dementia stage Alzheimer's disease. Clearance would mark a substantive logistical shift for the field: the first amyloid-directed monoclonal therapy deliverable as a once-weekly at-home auto-injection rather than a clinic-bound biweekly intravenous infusion.
Lecanemab is a humanised IgG1 monoclonal antibody that selectively binds soluble amyloid-beta protofibrils, accelerating clearance of the aggregated species implicated in synaptic dysfunction and neurodegeneration. The pivotal Clarity AD study reported a roughly 27 percent slowing of decline on a global cognitive-functional composite over 18 months — modest in absolute terms, but statistically robust and clinically meaningful in patients identified at the earliest, most treatment-responsive stage of the illness.
The case for a subcutaneous formulation is largely a real-world access argument. Biweekly IV infusions impose meaningful opportunity costs on patients and their caregivers, particularly outside large academic medical centres, and create chair-time constraints that have throttled uptake even where reimbursement pathways exist. A 360 mg weekly auto-injector — already used in maintenance protocols in clinical practice — extends the same active molecule into a delivery profile that can be self-administered or caregiver-administered at home with minimal training.
Approval would not eliminate the need for vigilance. Lecanemab continues to bear a boxed warning for amyloid-related imaging abnormalities — both edema (ARIA-E) and microhaemorrhage (ARIA-H) — with elevated risk in APOE ε4 homozygotes, and patients will still require scheduled MRI surveillance and clinical follow-up. Nonetheless, a home-administration option, if backed by appropriate patient selection and education, could materially broaden the population for which disease-modifying treatment becomes a realistic offer rather than a logistical hurdle.
- humanised
- Modified so that an antibody more closely resembles a human's own and is better tolerated.
- protofibril
- An early, soluble aggregate of amyloid-beta protein, smaller than a fully formed plaque.
- synaptic
- Relating to the connections between nerve cells.
- composite
- A measurement combining several outcomes into one score.
- uptake
- The rate at which a drug or service is actually used by patients.
- edema
- Swelling caused by extra fluid in tissue.
- homozygote
- A person who carries two copies of the same gene variant.
- disease-modifying
- Describes a therapy that changes the course of an illness, not just its symptoms.
